Roemer, Frank W. http://orcid.org/0000-0001-9238-7350
Jarraya, Mohamed
Collins, Jamie E.
Kwoh, C. Kent
Hayashi, Daichi
Hunter, David J.
Guermazi, Ali
Funding for this research was provided by:
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 22 August 2022
Revised: 19 September 2022
Accepted: 19 September 2022
First Online: 26 September 2022
Declarations
:
: Not applicable.
: Not applicable.
: FWR: Consultant to Calibr and Grünenthal. He is shareholder to of Boston Imaging Core Lab., LLC.MJ: Has no conflict of interest.JEC: Dr. Collins has received consulting fees from Boston Imaging Core Labs.CKK: CKK has received grants from Abbvie and EMD Serono and has provided consulting services for Astellas, EMD Serono, Thusane, Express Scripts and Novartis.DH: Has no conflict of interest.DJH: Dr. Hunter has received consulting fees from Merck Serono, TLC Biopharmaceuticals, Pfizer, and Eli Lilly and Company.AG: received consultancy fees from Pfizer, Novartis, MerckSerono, TissueGene, AstraZeneca, and Regeneron. His hsarhodr of Boston Imaging Core Lab., LLC.